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Abstract;   Since ancient times, drugs have been administered via the nasal route for therapeutic and recreational 
purposes. The interest in, and importance, of the systemic effects of drugs administered through the nasal route, have 
expanded over recent decades. Intra-nasal administration of drugs offers an interesting alternative for achieving 
systemic therapeutic effects of drugs that are comparable to the parenteral route, which can be inconvenient at times 
or oral administration, which can result in unacceptably low drug bioavailability. So, it is important to understand 
the potential and limitations of various nasal drug delivery systems. Therefore, the aim of this review article is to 
discuss the various pharmaceutical dosage forms that have the potential to be utilised for local or systemic drug 
administration. It is intuitively expected that this review will help to understand and further to develop suitable intra-
nasal formulations to achieve specific therapeutic objectives. 
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1. Introduction 
Nasal drug delivery, which is in the focus of this review article, 
has received a significant attention in recent years as a 
convenient and reliable route, not only for local but also for the 
systemic administration of drugs [1-3]. The nasal cavity offers a 
number of distinctive advantages for systemic delivery such as 
[4-6]:  
I- A large surface area for drug absorption. 
II- Convenience and good patient compliance. 
III- Rapid attainment of therapeutic drug levels in the blood.   
IV- High drug permeability, especially for lipophilic and low 
molecular weight drugs.  
V- Avoidance of harsh environmental and gastrointestinal 
conditions. 
VI- Bypassing of hepatic first-pass metabolism. 
VII- Potential direct drug delivery to the brain along the olfactory 
nerves.   
VIII- Direct contact site for vaccines with lymphatic tissues.  
The nasal cavity is an easily accessible route which is generally 
well tolerated [7]. The abundance of blood vessels in the nasal 
mucosa contributes to drug absorption, which is almost equal to 
intravenous injections in some instances [8]. The nasal route of 
drug delivery can be used for both local and systemic drug 
delivery [9]. For instance, localised nasal drug delivery is usually 
used to treat conditions related to the nasal cavity, such as 
congestion, rhinitis, sinusitis and related allergic conditions. A 
diverse range of drugs including corticosteroids, anti-histamines, 
anti-cholinergic and vasoconstrictors can be administered 
locally. In recent years, achieving a systemic drug action using 
the nose as the entry portal into the body has received more 
attention [10].  A wide range of pharmaceutical dosage forms 
including solutions, gels, suspensions, emulsions, liposomes and 
microparticles can be used to achieve systemic drug actions [11-
13]. These dosage forms are mostly designed to exploit the 
advantage of a rapid onset of action when administered via nasal 
route. For example, morphine [14] and ketamine [15] can be 
delivered intra-nasally to achieve rapid analgesic effects. 
Moreover, vaccines can also be administered using the nose as a 
potential route, such as those for influenza [16].  
2. Anatomy and physiology of nose 
The nose is the primary entrance to the respiratory tract, allowing 
air to enter into the body for respiration [11].  The nasal cavity is 
120-140 mm deep, runs from the nasal vestibule to the 
nasopharynx and is divided into two by a cartilaginous wall 
called nasal septum. The nose has a surface area of around 160 
cm2 and a total volume of  ~16-19 ml [12].   The nose serves as 
the mean of bringing warm humidified air into the lungs. It is the 
primary organ for filtering out particles in the inspired air, and it 
also serves to provide a first-line immunologic defence as it 
brings the inspired air into contact with the mucous-coated 
membrane. The nose has three main regions: vestibular, 
turbinate and olfactory regions (Figure 1). The vestibular region 
is the anterior part of the nose and it is the narrowest part of the 
nasal cavity. The vibrissae cover most of this area which renders 
it capable of filtering out particles with an aerodynamic particle 
size larger than 10 m that may be inhaled with air. In the 
vestibular region, the surface lining changes from skin, at the 
first part of the passage, to a stratified squamous epithelium [1,3]. 
The turbinate region is a large vascular part of the nose and can 
be divided into superior, middle and inferior regions (Figure 1). 
It is lined with a pseudostratified columnar epithelium. It is 
composed of mucus secreting, ciliated, non-ciliated and basal 
cells (Figure 2).  The ciliated and non-ciliated cells are covered 
with non-motile microvilli, which are responsible for increasing 
the surface area, thus, this is the region where the drug 
absorption is optimal. Ciliated cells are covered with 
approximately 100 motile cilia which are responsible for mucus 
transport so mucociliary clearance prevails. Once drug (as 
particles or in solution) find their way to the mucociliary area, 
they will be cleared from nasal cavity and then have limited 








Figure 1,  Sagittal section of the nasal cavity showing the nasal 
vestibule (A), atrium (B), respiratory area: inferior turbinate 
(C1), middle turbinate (C2) and the superior turbinate (C3), the 
olfactory region (D) and nasopharynx (E). Reproduced with 
permission from ref.  [20] 
The olfactory region is an area comprising about 8% of the total 
surface area of the nasal epithelium and is made of a non-
ciliated, pseudostratified columnar epithelium. It is important for 
transporting drugs to the brain and cerebrospinal fluid (CSF). 
There is a mucus layer of 5 µm in thickness covering the 
epithelium cells which traps unwanted particles. The mucous 
secretion consists of mucin, water, salts,proteins such as 
albumin, immunoglobulin, lysozyme, and lactoferrin, and lipids 








Figure 2, Cell types of the nasal epithelium with covering 
mucous layer showing ciliated cell (A), non-ciliated cell (B), 
goblet cells (C), mucous gel-layer (D), sol layer (E), basal cells 
(F) and basement membrane (G). Reproduced with permission 
from ref. [20] 
3. Biopharmaceutical consideration 
   The easy accessibility and higher surface area makes the nose a 
potentially viable drug delivery organ. Pharmaceutical product 
development is a crucial task which is directly dependent on its 
therapeutic objectives. Therefore, before product development, 
important biopharmaceutical aspects need to be considered-
firstly, whether it is intended for: 
I-    Localised delivery 
II-    Systemic delivery  
III-    Single or repetitive administration 
The feasibility of being able to achieve the therapeutic objectives 
will determine whether the development of a nasal delivery 
system is appropriate [5, 7, 10].  Comprehending the factors that 
can affect drug deposition, retention and absorption are essential 
to enable intelligent design of nasal formulations. Numerous 
physiological, anatomical, and pathological conditions must also 
be considered. Different types of nasal formulations available in 
the UK at the time of publication are enlisted in Table 1[22]. 
However, a major challenge in designing nasal drug delivery 
formulations is to introduce the drug into a suitable vehicle 
system that provides drug stability and ideal dispensing 
characteristics. Elements such as selection of specific 
pharmaceutical excipients, delivery devices and processing 
methods need careful consideration.  A schematic illustration of 
all the key parameters of a successful nasal formulation is shown 







Figure 3, Consideration of formulation elements of nasal 
product development.  
4. Nose as a drug delivery route: advantages and 
limitations 
    In addition to its benefits over parenteral routes in terms of 
convenience, the potential for delivering drugs directly into the 
brain along the olfactory nerves makes this route even more 
attractive [23]. The brain is a delicate organ with many vital 
functions and it is isolated and protected from the outside 
environment by several specific mechanisms. The blood-brain 
barrier (BBB), a tight tissue junction surrounding the brain, is 
one of such mechanisms resulting in a greater trans-endothelial 
electric resistance which hinders drug transport. 
Table 1, Current formulations for nasal drug delivery  [22] 
Table 2. Nasal drug absorption enhancers and mechanisms 
Class of compound  Example   Possible action  Reference 
Fatty acids Dideconoylphosphatidylcholine, 
lysophosphatidylcholine 
Membrane disruption [24] 
Surfactants Sodium lauryl sulphate, saponin, 
polyoxyethylene-9-lauryl ether 
Membrane disruption [25-28] 
Bile salts  Sodium deoxycholate, sodium 
glycocholate, sodium 
taurodihydrofusidate 
Open tight junctions, enzyme 




α-, ȕ-, Ȗ-cyclodextrin 
DMȕ-, HPȕ-cyclodextrin 
Open tight junctions, 
membrane disruption 
[32,33] 
Enzyme inhibitors Bestatin, amastatia Enzyme inhibition [34] 
Bio-adhesive materials Carbopol, starch microspheres, 
chitosan 
Reduce nasal clearance, open 
tight junctions 
[35] 
Indication Active pharmaceutical 
ingredient 
Formulation 
Analgesia Diamorphine hydrochloride 
 
Fentanyl citrate 
Powder and diluent for reconstitution-
aqueous spray Nasal spray, solution 
Acute treatment of migraine Sumatriptan 
Zolmitriptan 
Nasal spray, solution 
Nasal spray, solution 
Endometriosis 
Ovarian stimulation 
Nafarelin acetate Nasal spray, solution 
 
Nasal congestion (associated with 
sinusitis, common cold, rhinitis and 
other UTIs) 
Symptomatic relief of rhinorrhoea 
Xylometazoline hydrochloride 
Oxymetazoline hydrochloride 
Azelastine Hydrochloride  
Ephedrine 
Ipatropium bromide 
Nasal spray, solution, nasal drops  
Nasal spray, solution 
Nasal spray, solution 
Nasal drops 
Nasal spray, solution 
 
Prophylaxis and treatment of 
perennial and seasonal allergic 
rhinitis  
Budesonide,  






Fluticasone with azelastine HCl 
Sodium cromoglicate 
Nasal spray suspension 
Nasal spray suspension 
 
 
Nasal spray suspension 
Nasal spray suspension 
Nasal spray suspension 
Nasal spray suspension 
Nasal spray suspension,  
spray solution 
Prostatic carcinoma (hormone -
dependent) 
Buserelin acetate Nasal spray, solution 
 
Nasal congestion Levomenthol Nasal ointment 
Nasal infection Neomycin sulfate and Chlorhexidine 
dihydrochoride 
Nasal cream 
Nicotine withdrawal symptoms Nicotine Nasal Spray Solution 
Nocturia associated with multiple 
sclerosis  
The diagnosis and treatment of 
vasopressin-sensitive cranial 
diabetes insipidus. 
Establishing renal concentration 
capacity. 
 
Desmopressin acetate Nasal Spray Solution 
Vaccinations Influenza vaccine Nasal spray suspension 
In this context, over the last few years, an intra-nasal route has 
emerged as a promising approach for delivery of drugs to the 
brain. The delivery from the nose to the CNS may occur via the 
olfactory neuroepithelium and may involve paracellular, 
transcellular and/or neuronal transport [36]  with this olfactory 
pathway presenting the potential to bypass the BBB [37]. The 
nasal route can also be a useful alternative to the oral route for 
drug absorption in situations where a use of the gastrointestinal 
route is unfeasible. Examples include: patients with nausea and 
vomiting; patients with swallowing difficulties children and 
geriatrics [38]. The rate and extent of absorption as well as 
plasma concentration vs time profiles are comparable with I.V. 
administration [39]. 
The foremost limitation on adoption of the nasal route is that it is 
not applicable to all drugs.  The extent of drug absorption may 
depend on many physicochemical properties including acid-base 
dissociation constant (pKa) and partition coefficient, molecular 
weight, particle size and solubility of the drug [11]. In general, 
for a drug to be absorbed it must be in solution and this can be 
problematic for drugs with low solubility. For instance, polar 
drugs and some macromolecules are not absorbed in sufficient 
concentrations because of poor membrane permeability, rapid 
clearance, and enzymatic degradation within the nasal cavity 
[12]. The nasal mucosa is sensitive to local irritation by either 
drug or excipient [40]. Formulation factors such as the type of 
formulation (liquid, gel, and powder), excipient (solubilizer or 
absorption enhancer), drug concentration, pH and delivered 
volume also have a significant impact [41]. Physiological and 
anatomical factors include nasal blood flow, enzymatic 
degradation, mucociliary clearance and the physical condition of 
the nose; some conditions such as nasal atrophic rhinitis and 
severe vasomotor rhinitis can reduce the capacity of nasal drug 
absorption [38, 39] and the drug can be lost by dripping out of 
the nose or down the back of the throat, thus reducing 
bioavailability [13]. Nasal mucociliary clearance can also reduce 
contact time and drug absorption by transporting the drug to the 
nasopharynx and then to the gastric intestinal tract [42]. 
Mucociliary clearance can be overcome by incorporating 
mucoadhesive polymers into the formulation, which may 
increase nasal absorption [43].  The mucus layer can also be a 
barrier for drug absorption either by limiting drug diffusion or by 
binding drugs to mucins. Some conditions such as the common 
cold and hay fever can also change the conditions within the 
nose, either by increasing or decreasing mucociliary clearance, 
or altering the permeability of the absorbing mucosa. These 
limitations must be recognised and addressed when designing 
formulations to target drug absorption by the nasal route [44-47]. 
5. Mechanism of drug absorption 
The principal step in the absorption of a drug from the nasal 
cavity is the passage through the mucus. Fine particles easily pass 
through the mucus layer; however, large particles may find some 
difficulties [48]. Mucus contains mucin, a protein with the 
potential to bind with solutes and thus affect the diffusion process. 
Structural changes can occur within the mucus layer as a result of 
environmental or physiological changes [49]. Subsequent to a 
drug’s passage through the mucus, there are numerous 
mechanisms for absorption through the mucosa. These include 
transcellular or simple diffusion across the membrane, 
paracellular transport via movement between cell and transcytosis 
by vesicle carriers. Several mechanisms have been proposed, but 
paracellular and transcellular routes dominate [50].  
 Paracellular transport is slow and passive. There is an inverse 
correlation between intranasal absorption and the molecular 
weight of water-soluble compounds. Poor bioavailability was 
reported for drugs with a molecular weight greater than 1000 
Daltons [48].  
 The second mechanism involves transport through a lipoidal 
route that is also known as the transcellular process and is 
responsible for the transport of lipophilic drugs that show a rate 
dependency on their lipophilicity. Drugs also cross cell 
membranes by an active transport route via carrier-mediated 
means or transport through the opening of tight junctions [50]. 
Obstacles to drug absorption are potential metabolism before 
reaching the systemic circulation and inadequate residence time 
in the nasal cavity 
5.1. Drug absorption enhancement  
Many drugs having high water solubility have poor 
permeability across nasal epithelia and may present 
insufficient bioavailability. To enhance their permeation 
and bioavailability permeation enhancers are frequently 
employed [34]. In principle, permeation enhancers induce 
reversible modifications on the structure of the epithelial 
barrier. Although the exact mechanism of drug 
absorption/permeation enhancement is not well known, it 
is widely accepted that these materials modify the 
permeability of epithelial cell layer by modifying the 
phospholipid bilayer [35]. Different types of 
absorption/permeation enhancers are enlisted in Table 2 
with their possible mechanism of action. 
 6. Nasal drug delivery systems 
 6.1. Nasal drops and sprays 
   Nasal drops are one of the simplest and most convenient 
delivery systems among all formulations. The main 
limitation is the lack of precision in the administered 
dosage and the risk of contamination during use [51]. 
Nasal drops can be delivered with a pipette or by a squeezy 
bottle. These formulations are usually recommended for 
the treatment of local conditions, but challenges include 
microbial growth, mucociliary dysfunction and non-
specific loss from the nose or down back the throat [13,41]. 
  Nasal spray systems consist of a chamber, a piston and an 
operating actuator. Nasal sprays are comparatively more 
accurate than drops and generate precise doses (25 - 200 
µl) per spray [41]. Several studies have shown that nasal 
sprays can produce consistent doses of reproducible plume 
geometry. Formulation properties such as thixotropy, 
surface tension and viscosity can potentially influence 
droplet size and dose accuracy [52-55]. Other factors such 
as the applied force, orifice size and design of the pump 
can also affect the droplet size which can impact the nasal 
deposition of sprays [10, 13]. 
 6.2. Nasal gels 
   A gel is a soft, solid or semi-solid-like material 
consisting of two or more components, one of which is a 
liquid, present in substantial quantity. The semi-solid 
characteristics of gels can be defined in terms of two 
dynamic mechanical properties: elastic modulus G’ and 
viscous modulus G” [11].  The rheological properties of 
gels depend on the polymer type, concentration and 
physical state of the gel. They can range from viscous 
solutions (e.g. hypromellose, methylcellulose, xanthan 
gum and chitosan) to very hard, brittle gels (e.g. gellan 
gum, pectin and alginate). Bioadhesive polymers have 
shown good potential for nasal formulations and can 
control the rate and extent of drug release resulting in 
decreased frequency of drug administration and improved 
patient compliance [8, 56]. Moreover, the prolonged 
contact time afforded at the site of absorption can improve 
drug bioavailability by slowing down mucociliary 
movement [57]. Gavini et al. (2011) observed 
improvements in the solubility of roxithromycin loaded 
into chitosan microspheres compared with the free drug 
when the intranasal drug absorption was assessed in vivo in 
rats [58]. The mechanism of  mucoadhesion in the nasal 
cavity can be explained by a number of theories, but it is 
generally accepted that the mechanism is based on two key 
stages, the contact and consolidation stages. So, when 
formulations containing bioadhesive polymers are instilled 
in the nasal cavity, they can spread over the nasal 
epithelium. Due to the increased surface contact, the 
polymer chains can diffuse within the mucus. This creates 
sufficient contact for entanglement. Secondary chemical 
bonds are then formed between the polymer chains and 
mucin molecules [13]. Various biocompatible and 
biodegradable polymers have been used to formulate 
mucoadhesive systems. These include poly-vinyl alcohol 
[59], chitosan [60], carbopol, alginate, hydroxypropyl 
methylcellulose, hydroxypropyl cellulose, starch and 
gellan gum [13, 61]. Nasal administration using 
mucoadhesive gels has been studied for different drugs: 
antibiotics such as roxithromycin and ciprofloxacin [23], 
insulin [62], scopolamine hydrochloride [63], mometasone 
furoate [64], carvedilol [65], sumatriptan succinate [66], 
vaccines and proteins [67,68].  Ozsoy et al., 2000 [21] has 
investigated the formulation of ciprofloxacin hydrochloride 
using hydroxypropyl methylcellulose (HPMC) and the 
results suggested that the bioavailability of ciprofloxacin 
gel formulation prepared with HPMC was almost identical 
to the  oral route [23].  
In spite of most gels exhibiting shear-thinning behaviour 
(pseudoplasticity), some gel formulations with suitable 
rheological properties cannot be easily delivered using a 
normal nasal spray device. In situ gelation can be used to 
overcome this problem, [69] and has been investigated for 
the nasal delivery of mometasone furoate, carvedilol and 
influenza vaccine [66-69].  In such systems, the viscosity 
of the formulation must be low enough to allow dispensing 
from nasal spray device and viscous enough for adhesion 
on the application site.  
In situ gel-forming polymeric formulations are drug 
delivery systems that are in solution form before 
administration in the body, but once administered, undergo 
in situ gelation, to form a gel. The formation of gels 
depends on factors like temperature modulation, pH 
change and presence of ions from which the drug gets 
released in a sustained and controlled manner. Fluid gels 
are potential alternative to in situ gels. These fluid gels are 
essentially structured liquids containing a gel forming 
polymer. They are prepared by applying a shear force to 
the polymer solution during the gelation process. This 
results in  gelled particles suspended in an un-gelled 
polymer solution [70]. These can be formulated to behave 
as a viscoelastic liquid whilst maintaining a true gel 
microstructure within the gel particles. Recently, Mahdi et 
al., (2014) reported the development of a fluid gel 
formulation to achieve suitable viscoelastic properties to 
develop nasal sprays [13].   
6.3. Nasal suspensions and emulsions 
Suspensions are rarely used or investigated as nasal drug 
delivery systems. Analogous to marketed aqueous 
ophthalmic suspensions of the soft corticosteroid,  
loteprednol etabonate (e.g. Alrex®, Bausch and Lomb 
Pharmaceuticals), a nasal aqueous suspension of same drug 
containing microcrystalline sodium 
carboxymethylcellulose for stabilisation and retention in 
the nasal cavity was patented by Senju Pharmaceuticals 
Inc., Osaka, Japan [71] and was intended for the local 
treatment of allergic rhinitis. Moreover, a nasal suspension 
for the delivery of insulin was investigated by Ando et al. 
(1998) [72]. Here, soybean-derived steryl glycoside and 
sterol mixtures (1%) were used as absorption enhancers 
and pharmacological bioavailabilities of 6.7% and 11.3% 
were achieved. However, for oral drug delivery it has been 
reported by several authors [73-76] that emulsions were 
superior to suspensions in enhancing the bioavailability of 
poorly soluble drugs and the trend is similar with nasal 
formulations. Absorption enhancement has been attributed 
to solubilisation of the drug and the lipophilic absorption 
enhancers in the composition. Similarly, other low 
solubility compounds have been formulated in emulsions 
to increase the drug solubility, e.g. diazepam [77] and 
testosterone [78].  
Klang et al., 2015 [79] used a nano-suspension to target the 
brain through the nose. Formulation as a nanosuspension 
facilitated bypassing of the blood-brain barrier (BBB) for 
particles ranging between 1-500 nm. Moreover, recently 
researchers have also reported nasal administration of 
nano-emulsions for brain targeting [80-82]. 
6.4. Nasal micellar and liposomal formulations 
Different types of adjuvants can affect the drug absorption 
(described earlier, see section 5.1) and are often required to 
reach therapeutic plasma levels when hydrophilic 
macromolecular drugs such as peptides and proteins are 
delivered by the nasal route [83-85]. Among other 
surfactants used, bile salts are often used as enhancers, e.g. 
as micellar solutions. Tengamnuay and Mitra [86,87] 
described the use of micelles of sodium glycocholate and 
micelles thereof mixed with fatty acid (linoleic acid) as 
absorption enhancers for the model dipeptide (D-Arg2)-
kyotorphin and for insulin in rats. The effect of mixed 
micelles was synergistic and superior compared to the 
single enhancer. Mixed micelles of sodium glycocholate 
and linoleic acid reduced the blood glucose level after 
nasal insulin administration to 47% of the glucose level 
after an identical nasal dosage of unenhanced insulin. Pure 
sodium glycocholate resulted in a reduction to 55%. 
Regarding the mechanism, in a difference to the membrane 
solubilizing effect of pure bile salts, the mixed micelles 
were proposed to have an effect on the nasal paracellular 
pathway. Hereby, the bile salts were considered to act as 
solubilizing agents for the fatty acids thus making them 
more available at the nasal mucosa [86]. The absorption 
modifying effect of mixed micelles was reversible after 20-
40 min and the morphological alterations of the nasal 
mucosa were only mild to moderate after 5 h of exposure 
[86, 87]. However, measurement of marker enzymes in rat 
nasal perfusate showed that the damaging effect of mixed 
micelles on the epithelial membrane is significantly greater 
compared with pure sodium glycocholate solution and 
phosphate buffered saline after 90 min exposure [88].  
Liposomes have also been investigated as nasal drug 
delivery systems and absorption enhancing effects were 
found for insulin and calcitonin in vitro permeability 
studies [89]. The enhancement effect was attributed to 
increased nasal retention of peptides. The best carrier 
effect for calcitonin was demonstrated with cationic 
liposomes as they were found to adhere intimately to the 
nasal mucosal surface, facilitating the penetration of the 
encapsulated drug [89]. Similar observations were made 
for desmopressin-loaded cationic liposomes which resulted 
in enhanced antidiuretic effects in rats compared with 
anionic liposomes and solutions [90]. Muramatsu et al. 
(1999) [91] showed increased nasal absorption of insulin 
for liposomes of high membrane fluidity compared to more 
rigid particles. However, the absorption enhancing effect 
of liposomes is difficult to separate from the enhancing 
effects of the single components such as 
phosphatidylcholines and steryl glycosides. Moreover, 
proliposomes have also shown potential in nasal drug 
delivery. Proliposomes are dry, free-flowing granules 
composed of sorbitol as carrier and lipids that form a 
liposomal dispersion on contact with water. Their 
advantages are the combination of a fast onset (surface 
drug) and prolonged drug action (encapsulated drug) as 
demonstrated for propranolol and nicotine [92, 93]. 
6.5. Nasal powders 
Particulate nasal dosage forms are usually prepared by 
simply mixing the drug substance and the excipients [94-
95], by spray-drying or freeze- drying of drug [96-100]. 
Dry-powder formulations containing bioadhesive polymers 
for the nasal delivery of peptides and proteins was first 
investigated by Nagai et al. (1984) [101]. Water-insoluble 
cellulose derivatives and Carbopol® 934P were mixed 
with insulin and the powder mixture was administered 
nasally. The powder took up water, swelled, and 
established a gel with a prolonged residence time in the 
nasal cavity. Glucose reduction was one-third of that 
achieved using an i.v. injection of the same insulin dose. 
Powder formulations for nasal drug delivery have since 
been widely investigated, e.g. for a somatostatin analogue 
using cross-linked dextran and microcrystalline cellulose 
[102], for glucagon using microcrystalline cellulose [103], 
for leuprolide and calcitonin using microcrystalline 
cellulose in combination with hydroxypropyl cellulose 
[104], and for gentamicin sulfate using hydroxypropyl 
methylcellulose [99]. A bioadhesive powder containing 
beclomethasone dipropionate for local treatment of allergic 
rhinitis and hydroxypropyl cellulose as the carrier had a 
significantly enhanced nasal residence time compared with 
administration of a solution as drops [105]. Ugwoke et al. 
(2000) [97] compared the nasal retention time of 
apomorphine, freeze-dried with lactose, Carbopol® 971P or 
sodium carboxymethylcellulose. Three hours post 
insufflation, 58%, 12%, and 27%, respectively, of the 
formulation, had been cleared from the nasal cavity. In all 
cases, the administered powder reduced the nasal 
mucociliary clearance. The difference in nasal residence 
time led to a sustained plasma peak level from the 
Carbopol® formulation of 52 min vs. 11 min for the lactose 
powder while maintaining similar bioavailabilities [105]. 
Callens and Remon (2000) [98] demonstrated nasal insulin 
delivery with freeze-dried powders of waxy maize starch 
and Carbopol® 974P, reaching an absolute bioavailability 
of 14.4%. Comparison of different starch / Carbopol® 974P 
and maltodextrin / Carbopol® 974P mixtures by oscillatory 
rheology showed no synergistic increase in the viscosity 
and elasticity when combined with mucus, which is often 
used as an indicator of bioadhesion [106]. However, the 
formulation with the highest bioavailability had the highest 
storage modulus, i.e. the most solid-like properties. It was 
also observed that the insulin bioavailability was markedly 
reduced after repeated administration of the powder 
formulations [107]. Although the reasons remained 
unclear, it was speculated that the powders were not 
completely cleared from the nasal cavity after each 
delivery but formed a physical barrier on the nasal mucosa 
inhibiting penetration of the drug on subsequent 
administrations. Thus, bioadhesion seemed to have 
reversed into deteriorating the bioavailability. Also 
inorganic, water-insoluble powder formulations such as 
calcium phosphates enhanced the drug absorption in rats 
after nasal administration [95], although they did not 
promote the in vitro drug permeability across rabbit nasal 
mucosa [108]. Retardation at the site of administration was 
proposed as a possible explanation. 
 6.6. Nasal microparticles 
Using microparticles as another way of prolonging the 
residence time in the nasal cavity was introduced in 1987 
[109]. It was proposed that microspheres of albumin, starch, 
and DEAE-dextran (diethyl aminoethyl-dextran) absorbed 
water and formed a gel-like layer which was cleared 
slowly from the nasal cavity. Three hours after 
administration, 50% of the delivered amount of albumin 
and starch microspheres and 60% of the dextran 
microspheres were still present at the site of deposition. It 
was suggested that an increased contact time could 
increase the absorption efficiency of drugs. As proposed, 
the relative intranasal bioavailability (v.s. subcutaneous) of 
human growth hormone in sheep was increased from 0.1% 
for the solution to 2.7% for the degradable starch 
microsphere formulation. The addition of absorption 
enhancer, lysophosphatidylcholine, further enhanced 
growth hormone absorption as a relative bioavailability of 
14.4% was achieved [110]. Björk and Edman (1990) [111] 
showed that plasma glucose reduction after nasal insulin 
administration was comparable for degradable starch 
microspheres (cross-linked with epichlorohydrin) and 
insoluble starch powder (molecular weight 25 kDa) but 
significantly lower for soluble starch powder (molecular 
weight 11 kDa). It was therefore concluded that crucial 
parameters for the absorption promoting effect of 
microspheres are water absorption and aqueous insolubility. 
No alteration of the nasal mucosa was observable by 
scanning electron microscopy after 8 weeks of twice daily 
administration of starch microspheres, except slight 
hyperplasia in the septum wall [112]. Although DEAE-
dextran microspheres were retained strongly in the nasal 
cavity [109], they were not successful in promoting nasal 
insulin absorption in rats [113]. The insulin was too tightly 
bound to the DEAE-groups to be released by a solution 
with an ionic strength corresponding to physiological 
conditions. Dextran microparticles without ion exchange 
groups induced a 25% decrease in blood glucose level 
about 40 min after administration compared with initial 
levels. In a later study, dextran microspheres with a 
different distribution of the encapsulated insulin were 
compared [114]. When insulin was situated on the 
microsphere surface, a 52% reduction in plasma glucose 
was induced 30 min after administration in rats. However, 
microspheres, which included the insulin in the spherical 
matrix, reached a maximum plasma glucose level reduction 
of 30% after 60 min. Possibly, the limited amount of fluid 
in the nasal cavity is responsible for the observed 
differences, as the microspheres must be completely 
swollen to release the entire amount of incorporated insulin 
[115].  
Chitosan also has potential as an excipient in 
microparticulate drug delivery systems. In vivo studies in 
sheep showed a half-life of nasal clearance for chitosan 
microparticles of 115 min compared with 43 min for a 
solution of the polymer [116]. In general, chitosan 
formulations, whether in the form of microparticles or 
powders, were shown to provide a better absorption 
enhancing effect than chitosan solutions [117, 118]. 
Moreover, recently solid lipid nanoparticles have also 
shown promising results [119,120] and were shown to 
increase the brain targeting of rosmarinic acid following 
nasal delivery for potential management of Huntington’s 
disease [121].   
6. Conclusions   
Over last decade, the nasal cavity has become one the promising 
and potentially versatile route for delivering drugs. In particular, 
its unique capability of extending the drug release, by passing the 
hepatic first-pass metabolism and direct delivery of drugs to 
brain holds great promise in the field of drug delivery. A 
growing body of evidence relating to nasal drug delivery suggest 
it might the used for challenging drugs which can facilitate the 
pharmaceutical manufacturing and drug delivery challenges. 
Various pharmaceutical dosage forms and their potential to be 
utilised for local or systemic drug administration has been 
discussed in their review article. It is intuitively expected that this 
review will help to understand and further to develop the intra-
nasal formulations to achieve specific therapeutic objectives. 
However, a number of technical and practical issues, which are 
also highlighted in this review article, remain a hurdle to be 
overcome in order for the full potential to be realised.  
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